Commonly mutated gene could be a therapeutic target in sarcoma

  • The ATRX gene is commonly mutated in soft-tissue sarcomas, and its loss is linked to poorer outcomes in multiple sarcoma subtypes
  • Researcher identified a signaling pathway that helps explain how ATRX-deficient tumors grow and become more aggressive
  • ATRX-deficient sarcoma models responded better to investigational TEAD inhibitors
  • Findings suggest a potential precision medicine approach for patients with these difficult-to-treat cancers

Researchers at The University of Texas MD Anderson Cancer Center have discovered that sarcomas lacking the ATRX gene tend to be more aggressive and may be particularly vulnerable to a class of targeted therapies known as TEAD inhibitors. The findings identify ATRX loss as both a marker of poor prognosis and a potential therapeutic target.

The study, published in The Journal of Clinical Investigation , was led by Kunal Rai, Ph.D., professor of Genomic Medicine. If validated in future clinical trials, the results suggest ATRX – one of the most commonly mutated genes in sarcoma – could be a potential biomarker to guide treatment selection for patients with soft-tissue sarcomas.

“For many patients with sarcoma, treatment decisions still are not guided by the biology of their tumors,” Rai said. “We found that ATRX loss may identify patients who are more likely to benefit from TEAD inhibitors, creating a potential path toward precision medicine for these difficult-to-treat cancers.”

What is ATRX and why is it important in sarcoma?

Sarcomas are rare cancers with limited treatment options, particularly when the disease spreads. While ATRX is one of the most frequently altered genes in several sarcoma subtypes, researchers have not understood how these alterations influence patient outcomes or whether they could be targeted therapeutically.

The ATRX protein normally works to help organize chromatin, the tightly packed complex of DNA and proteins that forms chromosomes. To better understand the role of ATRX alterations in sarcoma, researchers evaluated tumor samples from patients with soft tissue and uterine leiomyosarcoma, undifferentiated pleomorphic sarcoma, and dedifferentiated liposarcoma.

ATRX loss was present in more than half of uterine leiomyosarcomas and in a substantial proportion of other sarcoma subtypes. Across multiple sarcoma types, loss of ATRX was associated with poorer outcomes, suggesting it may serve as a biomarker for more aggressive disease.

How does ATRX loss affect sarcoma cells?

Preclinical models confirmed that ATRX loss changes how sarcoma cells grow and behave. Tumors lacking ATRX grew faster, were more invasive and showed evidence of increased genomic instability.

Further investigation revealed that ATRX loss alters chromatin states, resulting in activation of a signaling pathway involving PRDM4, YAP1 and TEAD proteins. This pathway promotes cancer cell growth and survival, and it appears to play a central role in driving the aggressive behavior of ATRX-deficient tumors.

Could ATRX loss help identify new treatment opportunities?

Because ATRX-deficient tumors appeared to depend on YAP1-TEAD signaling, the researchers tested whether blocking this pathway could slow tumor growth. ATRX-deficient sarcoma cells and tumor models responded better to the investigational TEAD inhibitors VT103 and IAG933 than tumors with intact ATRX. Treatment reduced tumor growth and decreased activation of TEAD-controlled genes.

These findings suggest ATRX loss may create a therapeutic vulnerability that could be targeted with TEAD inhibition, providing a potential new treatment strategy for patients with ATRX-deficient sarcomas.

While additional clinical studies are needed to determine whether TEAD inhibitors will benefit patients, these findings identify ATRX loss as a potential biomarker that could help match patients with future targeted therapies and guide clinical trial development.

***

This research was supported in part by the National Institutes of Health, QuadW Foundation, National Leiomyosarcoma Foundation, Conquer Cancer the ASCO Foundation, Jay Vernon Jackson Liposarcoma Fund Foundation and UT MD Anderson institutional funding. For a full list of collaborating authors, disclosures and funding sources, see the full paper in The Journal of Clinical Investigation.

We found that ATRX loss may identify patients who are more likely to benefit from TEAD inhibitors, creating a potential path toward precision medicine for these difficult-to-treat cancers.

Aberrant nuclear morphology in ATRX-deficient cells